Search

Celldex Therapeutics Inc

Open

BrancheGesundheitswesen

40.74 4.27

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

38.46

Max

40.47

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.6M

-79M

Verkäufe

-60K

15K

EPS

-1.18

Gewinnspanne

-524,566.667

Angestellte

198

EBITDA

2.7M

-78M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+45.76% upside

Dividenden

By Acuity

Nächstes Ergebnis

5. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

386M

3B

Vorheriger Eröffnungskurs

36.47

Vorheriger Schlusskurs

40.74

Nachrichtenstimmung

By Acuity

50%

50%

175 / 340 Ranking in Healthcare

Celldex Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2026, 19:56 UTC

Celldex Therapeutics Inc shares are higher today, supported by overall market strength amid a decline in crude oil prices. No specific company news was identified.

3. Aug. 2026, 19:53 UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31. Juli 2026, 19:36 UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30. Juli 2026, 18:51 UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29. Juli 2026, 20:03 UTC

Macro Event
News

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28. Juli 2026, 19:36 UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27. Juli 2026, 19:31 UTC

News

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22. Juli 2026, 20:01 UTC

Event
News
Social Media

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21. Juli 2026, 23:01 UTC

Social Media
Event
News

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.

Peer-Vergleich

Kursveränderung

Celldex Therapeutics Inc Prognose

Kursziel

By TipRanks

45.76% Vorteil

12-Monats-Prognose

Durchschnitt 56.92 USD  45.76%

Hoch 100 USD

Tief 34 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Celldex Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

13

Buy

1

Halten

0

Sell

Stimmung

By Acuity

175 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat